Provided by Tiger Fintech (Singapore) Pte. Ltd.

Savara Inc

2.61
-0.1500-5.43%
Post-market: 2.610.00000.00%17:38 EDT
Volume:901.81K
Turnover:2.39M
Market Cap:447.93M
PE:-6.13
High:2.94
Open:2.77
Low:2.57
Close:2.76
Loading ...

Savara Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
13 Nov 2024

Evercore ISI Downgrades Savara to In Line From Outperform, Adjusts Price Target to $5 From $7

MT Newswires Live
·
13 Nov 2024

Savara Announces Participation in Upcoming Healthcare Conferences

Business Wire
·
13 Nov 2024

Savara Cut to In-Line From Outperform by Evercore ISI Group

Dow Jones
·
13 Nov 2024

Savara Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
12 Nov 2024

Savara Q3 EPS $(0.11), Inline

Benzinga
·
12 Nov 2024

Savara Inc: Sufficiently Capitalized Through 2Q 2027

THOMSON REUTERS
·
12 Nov 2024

Savara Inc: Updates Guidance on Molbreevi Bla Submission Completion Date to End of 1Q 2025 From 1H 2025

THOMSON REUTERS
·
12 Nov 2024

Savara Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
08 Oct 2024

Evercore ISI Remains a Buy on Savara (SVRA)

TIPRANKS
·
01 Oct 2024

Savara Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
01 Oct 2024

Savara Initiates Early Access Program for Rare Lung Disease Treatment

MT Newswires Live
·
27 Sep 2024

BRIEF-Savara Announces Expanded Access Program For Molgramostim Inhalation Solution For Patients With Autoimmune Pulmonary Alveolar Proteinosis

Reuters
·
27 Sep 2024

Savara : Savara Early Access Accepting Requests From Patients in Select Countries in N.america & Europe, Plans to Expand Through 2026

THOMSON REUTERS
·
27 Sep 2024

Savara Inc: Plans to Complete Submission of a Bla to FDA for Molgramostim in Apap in H1 of 2025

THOMSON REUTERS
·
27 Sep 2024

Savara Announces Expanded Access Program (Eap) for Molgramostim Inhalation Solution (Molgramostim) for Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap)

THOMSON REUTERS
·
27 Sep 2024